

Curriculum Vitae

* Within 3 pages

	Name in Full	Sung Eun Kim
	Country	Republic of Korea
	Affiliation	Division of Gastroenterology, Department of Internal Medicine, Kosin University College of Medicine
	Email	solefide@hanmail.net

Educational Background

1998.03.01–2004.02.28
 : Kosin University School of Medicine, Medical Science, Bachelor's degree
 2006.03.01–2008.02.28
 : Kosin University School of Medicine, Medical Science, Master's degree
 2012.03.01–2014.02.28
 : Kosin University School of Medicine, Medical Science, Doctor's degree

Professional Career

2011.03.01–2012.02.29: Research Fellow, Division of Gastroenterology, Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea
 2012.03.01–2013.02.28: Research Fellow, Division of Gastroenterology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea
 2013.03.01–2019.03.31: Assistant Professor, Division of Gastroenterology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea
 2019.04.01–2024.03.31: Associate Professor, Division of Gastroenterology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea
 2019.09.01 –2021.08.31: Visiting scholar, Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA
 2024.04.01–Present: Professor, Division of Gastroenterology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea



Research Field

Hollow viscus (Upper gastrointestinal disorders)

- *Helicobacter pylori*
- Gastrointestinal motility disorders
- Therapeutic endoscopy
- Gastric cancer, esophageal cancer

Koh M, Choi CW, Ryu DG, Yu SJ, **Kim SE**, Jung K, Lee BE, Lee MW, Joo DC, Lee J, Cha RR, Jee SR. Fourteen-Day Amoxicillin- or Tetracycline-Containing Bismuth Quadruple Therapy versus 14-Day Metronidazole-Based Triple Therapy as the Treatment for Clarithromycin-Resistant *Helicobacter pylori* Infection: A Multicenter Randomized Controlled Trial. Gut Liver. 2026 Sep 15;20(5):756-764.

Bang CS, Kang SJ, Lim H, Kim SH, Lee MW, Nam SY, Tae CH, **Kim SE**, Kim SY, Jung HK, Kim BJ, Choi M, Jung HY, Kim BW; Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Diagnosis and Treatment of *Helicobacter pylori* Infection in Korea: 2025 Revised Edition. Helicobacter. 2026 Jul-Aug;31(4):e70149.

Kim BJ, Kang SJ, Nam SY, Bang CS, Min BH, **Kim SE**, Kim SY, Lim H, Tae CH, Lee MW, Kim SH, Kim SH, Lee JY, Kim BW, Moon JS, Park JJ, Jung HY; Korean College of Helicobacter and Upper Gastrointestinal Research. Practice Guidelines for the Diagnosis and Treatment of Subepithelial Lesion Observed in Upper Gastrointestinal Endoscopy. J Gastroenterol Hepatol. 2026 Feb;41(2):488-501.

Kim SH, Park JY, Lee A, Lee BE, Min BH, Park CH, Jung DH, Jo HH, Chung H, Yoo IH, Park SY, Lee SW, Choi Y, Lee JH, Kim SH, Park JM, Kim JS, **Kim SE**, Jung HY. Current Practices in Histological Diagnosis and Management of Asymptomatic Gastric Subepithelial Lesions: A Multicenter Survey in Korea. Korean J Helicobacter Up Gastrointest Res. 2025 Jun;25(2):159-166.

Son MY, Cho DH, **Kim SE**, Park SJ, Park MI, Moon W, Kim JH, Lee JW, Jung K. Long-Term Outcomes and Risk Factors for Lymph Node Metastasis in Siewert Type II/III Early Gastric Cancer. Korean J Helicobacter Up Gastrointest Res. 2024 Sep;24(3):252-258.

Lee JY, **Kim SE**, Park SJ, Park MI, Moon W, Kim JH, Jung K. *Helicobacter pylori* infection and iron deficiency in non-elderly adults participating in a health check-up program. Korean J Intern Med. 2022 Mar;37(2):304-312.

Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, **Kim SE**, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence based guidelines for the treatment of *Helicobacter pylori* infection in Korea 2020. Gut Liver. 2021 Mar 15;15(2):168-195.

Lee YD, **Kim SE**, Park SJ, Park MI, Moon W, Kim JH, Jung K, Song J. Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with *Helicobacter pylori* Infection. Korean J Gastroenterol. 2020 Sep 25;76(3):142-149.



Seo KI, Heo JJ, **Kim SE**, Park SJ, Park MI, Moon W, Kim JH, Jung K, Cho DH. Sex differences between *Helicobacter pylori* infection and cholesterol levels in an adult health checkup program. *Helicobacter*. 2020 Aug;25(4):e12704.

Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kwon HJ, Kim GM, Joo HK. Mosapride Improves Lower Esophageal Sphincter and Esophageal Body Function in Patients with Minor Disorders of Esophageal Peristalsis. *J Neurogastroenterol Motil*. 2020 Apr 30;26(2):232-240.

Jung HK, Hong SJ, Lee OY, Pandolfino J, Park H, Miwa H, Ghoshal UC, Mahadeva S, Oshima T, Chen M, Chua ASB, Cho YK, Lee TH, Min YW, Park CH, Kwon JG, Park MI, Jung K, Park JK, Jung KW, Lim HC, Jung DH, Kim DH, Lim CH, Moon HS, Park JH, Choi SC, Suzuki H, Patcharatrakul T, Wu JCY, Lee KJ, Tanaka S, Siah KTH, Park KS, **Kim SE**; Korean Society of Neurogastroenterology and Motility. 2019 Seoul Consensus on Esophageal Achalasia Guidelines. *J Neurogastroenterol Motil*. 2020 Apr 30;26(2):180-203.

Oh JH, Kwon JG, Jung HK, Tae CH, Song KH, Kang SJ, **Kim SE**, Jung K, Kim JS, Park JK, Bang KB, Baeg MK, Shin JE, Shin CM, Lee JY, Lim HC; Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. *J Neurogastroenterol Motil*. 2020 Jan 30;26(1):29-50.

Kim SE, Kim N, Park YS, Kim EY, Park SJ, Shim KN, Choi YJ, Gwak GY, Park SM. Importance of a Diversity Committee in Advancing the Korean Society of Gastroenterology: A Survey Analysis. *Korean J Gastroenterol*. 2019 Sep 25;74(3):149-158.

Ong S, **Kim SE**, Kim JH, Yi NH, Kim TY, Jung K, Park MI, Jung HY. *Helicobacter pylori* eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: A multicenter randomized controlled trial. *Helicobacter*. 2019 Oct;24(5):e12654.

Kim SE, Roh JH, Park MI, Park SJ, Moon W, Kim JH, Jung K, Heo JJ. Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line *Helicobacter pylori* Eradication Therapy. *Korean J Gastroenterol*. 2019 Jan 25;73(1):26-34.

